Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas

Phase 1 Terminated 47 enrolled Chinook Therapeutics, Inc. Novartis Pharmaceuticals · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity of MIW815 (ADU-S100) administered via intratumoral injection as a single agent and in combination with ipilimumab.

Timeline

Start: 2016-04-28
Primary completion: 2019-12-11
Completion: 2020-08-06

Publications

Gogoi H, Mansouri S, Jin L. The Age of Cyclic Dinucleotide Vaccine Adjuvants. Vaccines (Basel). 2020 Aug 13;8(3):453. doi: 10.3390/vaccines8030453.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ADU-S100	Other / unclassified	50 ug	Other
Subject	ADU-S100	Other / unclassified	200 ug	Other
Subject	Ipilimumab	Monoclonal antibody	3 mg/kg	Intravenous

Indications

No indication recorded.